

# Metabolomic analysis of *T. congolense* treated with isometamidium chloride and in silico modeling of potential drug targets

Laurah N. Ondari<sup>1,2\*</sup>, Suhaila O. Hashim<sup>2</sup>, Pieter Steketee<sup>3</sup>, Daniel Masiga<sup>1</sup>, Michael P. Barrett<sup>4</sup>

<sup>1</sup>International Center of Insect Physiology and Ecology (*icipe*), <sup>2</sup>Department of Biochemistry and Biotechnology, Pwani University. P.O. Box 195-80108 Kilifi, Kenya, <sup>3</sup>The Roslin Institute, University of Edinburgh, Midlothian EH25 9RG, UK, <sup>4</sup>School of Infection and Immunity, University of Glasgow, Glasgow G12 8QQ, UK londari@icipe.org

# INTRODUCTION

- Animal African Trypanosomiasis (AAT) is a serious and fatal parasitic disease in Africa that is transmitted by *Glossina* species.
- AAT is caused by various Trypanosoma species including T. congolense, T. *vivax*, and *T. brucei*<sup>1</sup>. The disease affects about 50 million animals and causes losses of about 4.5 million USD p.a<sup>1</sup>.
- Six compounds are licensed for treatment of AAT and the most commonly used are diminazene aceturate (DZ) – first-line drug, isometamidium chloride (ISM) – for prophylaxis and treatment, and homidium salts.
- Control against AAT is heavily dependent on chemotherapy with  $\sim$  35 mil.

# RESULTS







doses/yr administered to prevent progression in endemic areas<sup>2</sup>. However, efforts to eliminate AAT have been hindered by resistance, toxicity, poor efficacy, and limited knowledge or lack thereof of the mechanism of action (MOA) of existing drugs.

### **OBJECTIVES**

- To investigate how **ISM** impacts the metabolome of *T. congolense* and identification of potential drug targets.
- To infer the interaction mechanisms of **ISM** against identified drug targets through in silico modeling.



Figure 1: a. Treated samples clustered closely on the Principal Component Analysis (PCA) plot where 49.8% variance was observed between the first 2 principal components. **b.** Clustering heatmap of dysregulated metabolites showing distinct clustering between the control and treatment groups.

#### 2. Can metabolomic analysis aid the identification of ISM drug targets? Why do NTPs decrease and NMPs and un-phosphorylated nucleosides increase?





autoscaling

- PCA, One-way ANOVA with Tukey's HSD post hoc
- Volcano plot analysis
- Clustering heatmap



BIOVIA

Molecular docking and visualisation

### CONCLUSIONS

- Statistical and metabolomic analysis identified possible competitive inhibition of  $\bullet$ the *T. congolense* glucose transporter which was further evidenced in the molecular docking assay where isometamidium chloride interacted with the same substrate binding site as glucose.
- Owing to the lower energy of binding displayed by isometamidium chloride it is possible that isometamidium chloride has a higher competitive affinity for TcoHT1 compared to glucose.

**Figure 2**: **a.** Classic glycolysis in PCF *T. brucei* that is hypothesized to resemble BSF T. congolense<sup>3</sup>. **b.** The nucleotide phosphorelay system in Pseudomonas fluorescens<sup>4</sup>.

3. Interaction of ISM and the T. congolense glucose transporter (TcoHT1)



Figure 3: a. Interactions of glucose with the predicted T. congolense glucose

### IMPACT

- Metabolomic and molecular docking analyses show that **ISM** impacts the metabolome of *T. congolense* by interacting with the substrate binding site of the glucose transporter.
- This study identified the potential drug target for **ISM**. These findings provide new insights into the mechanism of action of **ISM** and suggest avenues for future drug development efforts.



International Centre of Insect Physiology P.O. Box 30772-00100, Nairobi, Kenya

E-mail: <u>icipe@icipe.org</u>

www.icipe.org

transporter (TcoHT1)(-5.7 kcal/mol). b. Interactions of ISM with the predicted T. congolense glucose transporter (TcoHT1) (-10.1 kcal/mol).

# ACKNOWLEDGEMENT

We gratefully acknowledge Glasgow Polyomics who generated the data used in this study.

### REFERENCES

- 1. Yaro et al., (2016). Veterinary Parasitology, 225, 43–52.
- 2. Richards et al., (2021). Trends in Parasitology, 37(9), 831–843.
- Michels et al., (2021). Experimental Parasitology, 224.
- 4. Appanna at al., (2016). Archives of Biochemistry and Biophysics, 606, 26–33.

